含顺铂与不含顺铂方案治疗晚期食管癌的临床分析

Clinical observation of chemotherapy regimen with and without cisplantin for advanced esophageal carcinoma

目的:探讨晚期食管癌的化疗疗效及预后。方法:对行化疗的83例晚期食管癌患者临床资料进行回顾性分析。化疗按含顺铂(59例)及不含顺铂(24例)方案分两组。结果:化疗的总有效率为30.0%。化疗后中位生存期为7个月,1、2年生存率分别为37.3%和7.7%。含顺铂方案的有效率为37.3%,高于不含顺铂方案的12.5%,差异有统计学意义,χ2=4.98,P=0.026。化疗有效患者的中位生存期为13个月,明显长于化疗无效患者的6个月,差异有统计学意义,Logrank值为7.59,P=0.0059。结论:食管癌化疗应首选含顺铂的方案,初次化疗有效能明显延长患者的生存期。

OBJECTIVE：To study the effects and prognosis of chemotherapy in the treatment of advanced esophageal cancer.METHODS：83 patients with advanced esophageal carcinoma who were treated were analyzed retrospectively.All cases were classified into two groups according to cisplantin regimen（59 cases）or not（24 cases）.RESULTS：The overall response rate was 30.0%.The median survival time was 7 months.The 1-year and 2-year survival rates were 37.3% and 7.7% respectively.The response rate of cisplatin regimens（37.3%）was more than that of non-cisplatin regimens（12.5%）.Difference was statistically significant,χ^2=4.98,P=0.026.The median survival time of patients who were effectively treated by chemotherapy（13 months）was obviously longer than that of patients who were not effectively treated by the chemotherapy（6 months）.Difference was statistically significant,log rank value was 7.59,P=0.005 9.CONCLUSION：Cisplantin-based regimens should be the first choice of chemotherapy regimens for esophageal carcinoma and survival time was significantly prolonged if the initial chemotherapy was effective.